drugset / Trial / NCT05452434
Mirabegron Combined With Behavioral Intervention for Overactive Bladder:a Prospective Multicenter Randomized Controlled Clinical Study
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to assess the efficacy, safety and tolerability of Mirabegron and behavioral combination versus Mirabegron alone in the treatment of women with overactive bladder (OAB).
Timeline
- Start
- 2022-07-15
- Primary completion
- 2023-07-15
- Completion
- 2023-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirabegron | Other / unclassified | 50 mg | — |